New York, December 16, 2015 -- Moody's Investors Service commented that Valeant faces execution risk as it faces transition in its dermatology business and certain other product lines. However, the recent deal with Walgreens is credit positive, as is management's continuing emphasis on debt reduction during 2016. There are no changes to Valeant's ratings including the Ba3 Corporate Family Rating or the stable rating outlook.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.